Pelago Bioscience AB

Spun out from the Karolinska Institute in 2013, Pelago Bioscience AB was founded by the inventors of the Cellular Thermal Shift Assay (CETSA®) to both develop the method and to provide a commercial service for organisations wanting to use the method.. . CETSA measures compound binding under actual physiological conditions within either a cellular of lysate environment. The assay relies on a well-established observation that compound binding with a protein will change its thermal denaturation point, meaning that at a given denaturation temperature there will be a difference in the abundance of the intact protein as compared with a negative control. It is the only technique that will confirm such target engagement is occurring and provides ‘real world’ EC50 values for your compound in cells.. . The company controls the patents on CETSA and delivers in situ target engagement studies to accelerate preclinical and clinical drug discovery and diagnostics development. Using CETSA data and applications, drug discovery R&D companies are able to make better and more informed decisions at earlier stages in their projects.